Delivery Order SPE2DB20D1110-SPE2DB25FK42N
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $3,351.92 to AmerisourceBergen Drug Corp for CAPLYTA 42 mg capsules (30-count units) on August 6, 2025, with an ultimate completion date of August 7, 2025. This is a firm fixed-price, non-set-aside contract to be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for CAPLYTA 42 mg capsules (30-count units) valued at $4,244.31 under a firm fixed-price contract type. The award was made on May 6, 2025, with an ultimate completion date of May 7, 2025, and represents a non-set-aside competitive award. This delivery order is a child contract executed under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a comprehensive...
- The Defense Logistics Agency awarded a $3,203.19 delivery order to AmerisourceBergen Drug Corp for CAPLYTA 42 MG capsules (30-count units) on August 28, 2025, with completion by August 29, 2025. This non-set-aside, firm fixed-price contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.99 billion comprehensive pharmaceutical support vehicle running through December 2026. The product will be...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for CAPLYTA 42 mg capsules (30-count units) valued at $1,067.73 under a firm fixed price contract. The award was made on August 7, 2025, with an ultimate completion date of August 8, 2025, and represents a non-competitive delivery order. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will fulfill this order from its Corporate Office location, serving the federal medical supply chain...
- The Defense Logistics Agency awarded a delivery order valued at $10,244.42 to AmerisourceBergen Drug Corp for the supply of CAPLYTA 42 mg capsules (30-count units). The contract, issued on July 21, 2025, with an ultimate completion date of July 22, 2025, utilizes firm fixed-price pricing and carries no set-aside designation, indicating it was competitively awarded. The place of performance is listed as AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery...
- The U.S. Department of Defense Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of CAPLYTA 42 mg capsules (30-count units) under a firm fixed-price contract valued at $13,672.67. The delivery order, which serves as a child contract to a larger vehicle, is set to be completed by July 28, 2025. This award was competitively procured with no set-aside designation and reflects AmerisourceBergen's role as a critical pharmaceutical...
- The U.S. Defense Logistics Agency (DLA) Troop Support Medical awarded a Firm Fixed Price Delivery Order contract to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation, to provide CAPLYTA 21 MG CAPSULE 30S pharmaceutical products. The $3,514.35 contract has a completion date of January 11, 2024. AmerisourceBergen Drug Corp is the prime contractor, with no set-aside designation mentioned. As a global pharmaceutical sourcing and distribution services company,...
- The Defense Logistics Agency awarded a $22,965.13 firm fixed-price delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of CAPLYTA 10.5 mg capsules (quantity: 30 units). This is a competitively awarded contract with no set-aside designation, with performance to be completed by September 4, 2025, and fulfillment occurring at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under...
- The Defense Logistics Agency awarded a delivery order valued at $4,196.74 to AmerisourceBergen Drug Corp for CAPLYTA 21 mg capsules (30-count units) on August 4, 2025, with completion scheduled for August 5, 2025. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded to the prime contractor. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 1, 2025, for the supply of CAPLYTA 42 mg capsules (30-count units) valued at $3,348.66 under a firm fixed-price contract. This is a non-set-aside competitive award with an ultimate completion date of August 4, 2025, with performance to be fulfilled at the vendor's Conshohocken, Pennsylvania facility. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery...
- SPE2DB20D1110Indefinite Delivery Contract
- SPE2DB20D1110-SPE2DB25FK42NDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $11,458.54 to AmerisourceBergen Drug Corp for CAPLYTA 42 MG capsules (30-unit supply). The contract is firm fixed price with no set-aside designation and is scheduled for completion by September 18, 2025. This delivery order represents a competitive award under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 prime vendor agreement running through December 2026 that enables the company to supply pharmaceutical products and medical supplies globally to support military healthcare programs. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a major pharmaceutical distributor for federal medical procurement needs, particularly supporting military and veteran healthcare systems. The company's contract portfolio with DLA encompasses a comprehensive range of medications across multiple therapeutic domains, including specialty drugs, brand-name and generic pharmaceuticals, and related medical supplies. CAPLYTA (lumateperone) is an atypical antipsychotic used in the treatment of schizophrenia and bipolar depression, reflecting the breadth of psychiatric and neurological medications included in the company's federal supply capabilities.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $11.5k | 9/17/25 |